retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 ๐ง๐ต๐ฒ ๐๐ณ๐ณ๐ฒ๐ฐ๐ ๐ผ๐ณ ๐๐๐ฃ-๐ญ ๐ฅ๐ฒ๐ฐ๐ฒ๐ฝ๐๐ผ๐ฟ ๐๐ด๐ผ๐ป๐ถ๐๐๐ ๐ผ๐ป ๐๐น๐๐ฐ๐ฎ๐๐ฒ๐ฑ ๐๐ฒ๐บ๐ผ๐ด๐น๐ผ๐ฏ๐ถ๐ป ๐๐ฒ๐๐ฒ๐น๐ โฃ โฃ Randomized, placebo-controlled trials of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong Phase 2 Trial of Retatrutide
Description
Each visit should cover your weight trajectory, side effect management, metabolic markers (periodic lab work), medication adherence, and any new symptoms or concerns

The gut hormones PYY 336 and GLP-1 736 amide reduce food intake and modulate brain activity in appetite centers in humans
Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose

Clinicians must nevertheless balance these impressive cardiovascular benefits against practical considerations

In 2024, the Western Pacific had approximately 215 million adults with diabetes, while Southeast Asia accounted for another 106.9 million, creating a vast potential patient pool
